COVID ups risks of dementia, cognitive impairment, and decline in older survivorsSadly and not surprisingly, the science media is reporting that the neurological impact of covid 19 is showing increased levels of cognitive decline worldwide. Older adults are having to cope with damage to their lungs and central nervous system. The study noted that the telephone survey measures used were limited in identifying more specific challenges and likely underestimate the size of the problem due to having excluded subjects with any family history of dementia. The global dementia care burden is likely to be greater as a result of the COVID-19 pandemic and so there is even greater need to rapid intervention now that can be easily, safely and cost effectively deployed. Researchers and clinicians at Quietmind Foundation, Neuronic Devices Ltd (Neuronic.online), Baylor Research Institute and the Biophotonic and Neuroimaging Lab•UTexas-Arlington are collaborating to show the effectiveness of self-administered, transcranial infrared light-based therapy to reduce dementia's cognitive and behavioral symptoms.
The Neuradiant 1070 4Q technology that's being released this month by Neuronic Devices Ltd. (see Neuronic.online) is a resource that can address the debilitating impact of COVID 19 on the brain by increasing cortical perfusion and ATP production by stimulating cytochrome c oxidase and improving blood vessel flexibility. In addition, the new independent 4 -quadrant control of pulse frequency allows for renormalization of dysregulated brain network connectivity using the light pulsations to directly changes in EEG activity.
Mental disorders in early life are associated with a significantly increased risk of dementia in later years.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.